BAY 1021189 clinical trials

(21683) Phase 2b open-label clinical study to evaluate the tolerability and safety of an initiation dose of 5 mg of Vericiguat in participants with chronic heart failure with reduced ejection fraction

This study is testing a new 5mg dose of a drug called Vericiguat for people with long-term heart failure where their heart doesn’t pump blood well. We want to see how well people tolerate this starting dose and if it's safe to use. It's an early-stage study.